EXECUTIVE SUMMARY

ISO-17025 accredited bioanalytical laboratory serving pharmaceutical, biopharma, and peptide markets with comprehensive testing capabilities and a strong growth trajectory. The company offers USP, EP, and JP-compliant raw material testing, biomolecule characterization, chromatography, mass spectrometry, microbiological analysis, and assay development services.

BUSINESS OVERVIEW

This established bioanalytical laboratory holds ISO 17025 accreditation and specializes in pharmaceutical and biological product characterization. The facility serves pharmaceutical, biopharma, and nutraceutical clients with particular strength in the expanding peptide and biologics sectors. The laboratory's multi-pharmacopeia capabilities (USP, EP, JP) position it strategically for multinational pharmaceutical companies requiring regulatory compliance across multiple jurisdictions.

CORE SERVICES & CAPABILITIES

• Raw material testing compliant with USP, European Pharmacopeia, and Japanese Pharmacopeia standards
• Biomolecule characterization, including vaccines and peptides
• Advanced chromatography and mass spectrometry analysis
• Microbiological testing, PCR, and endotoxin analysis
• Pharmaceutical method development and biological assay development
• Product and formulation development support

MARKET POSITION

The laboratory operates in the specialized bioanalytical testing market, serving both established pharmaceutical companies and emerging biotechnology firms. The facility's versatility in handling conventional pharmaceutical and biopharma products provides competitive differentiation in an increasingly biologics-focused market.

FINANCIAL PERFORMANCE

2025 Financial Results:
• Revenue: $461,000
• Seller's Discretionary Earnings: $180,000

2026 Projections:
• Revenue: $1,000,000
• Seller's Discretionary Earnings: $400,000

Recent performance indicators demonstrate strong momentum with average monthly revenue of $66,000 over the past six months and January 2026 revenue of $85,000.

MANAGEMENT & OPERATIONS

The laboratory is managed by a Ph.D. scientist with extensive expertise in analytical chemistry, mass spectrometry, and pharmaceutical quality testing. The management team has successfully assembled qualified technical staff and established standardized workflows supporting consistent service delivery.

TRANSACTION STRUCTURE

Offering: 75% equity stake
Asking Price: $400,000

The transaction structure allows the buyer to assume operational control while retaining the founder's technical expertise and institutional knowledge. The existing management team remains committed to continued operations and growth.

GROWTH OPPORTUNITIES

The established platform supports expansion into higher-volume peptide and biologics testing, deeper pharmaceutical client penetration, and expanded development services. With enhanced commercial reach and strategic partnerships, the laboratory is positioned to scale revenue to the multi-million-dollar range.